{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:48:11Z","timestamp":1783475291050,"version":"3.55.0"},"reference-count":13,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2007,6,16]],"date-time":"2007-06-16T00:00:00Z","timestamp":1181952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:p>\n                    <jats:bold>Background.\u2014<\/jats:bold>\n                    Basilar\u2010type migraine (BM) is the most common migraine \u201cvariant,\u201d representing 3\u201019% of migraine in children.BMis characterized by attacks of dizziness, vertigo, visual disturbances, ataxia, and\/or diplopia, followed by migraine headache.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective.\u2014<\/jats:bold>\n                    The objective of this study is to assess the efficacy and safety of topiramate for prophylaxis of BM in children and adolescents (6\u201018 years).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design.\u2014<\/jats:bold>\n                    Outpatient, double\u2010blind, parallel\u2010group, dose comparison study with 2 phases: prerandomization (screening\/washout and 4\u2010week prospective baseline) and 12\u2010week double blind (titration and maintenance).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods.\u2014<\/jats:bold>\n                    Following consent and assent, subjects with BMs, as defined by the International Classification of Headache Disorders (second edition), and \u22654 migraines\/month were randomized to receive either 25\u2003mg per day or 100\u2003mg per day of topiramate in a 1\u2003:\u20031 ratio.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.\u2014<\/jats:bold>\n                    Fourteen children (4 boys, 10 girls) completed the double\u2010blind phase (7 in the 25\u2010mg group and 7 in the 100\u2010mg group). During the prospective baseline, the mean headache frequency of the combined group \u201call migraines\u201d per month was 4.5\/month (25\u2003mg) and 4.8\/month (100\u2003mg). Average duration of migraine was 5.5 hours (25\u2003mg) and 5.0 hours (100\u2003mg) and average mean pain (5\u2010point faces scale) was 3.3 for both (25\u2003mg 100\u2003mg).\n                  <\/jats:p>\n                  <jats:p>\n                    The reduction in median monthly migraine rate during the double\u2010blind treatment phase relative to baseline was 2.9 (64.4%) and 3.6 (75.0%) for the 25\u2010mg and 100\u2010mg topiramate\u2010treated groups, respectively (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u2003.001).\n                  <\/jats:p>\n                  <jats:p>\n                    The reduction in median monthly BM rate during the double\u2010blind treatment phase relative to baseline was 2.5 (74.24%) and 2.3 (82.8%) for the 25\u2010mg and 100\u2010mg topiramate\u2010treated groups, respectively. The overall reduction in BM attacks reduced from 2.84\/month to 0.59\/month (79.2%;\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u2003.0042).\n                  <\/jats:p>\n                  <jats:p>\n                    Overall, 86% of patients responded with a greater than 50% reduction in migraine frequency (100%, 25\u2003mg and 71%, 100\u2003mg). Mean reduction in migraine duration was 18 minutes (25\u2003mg) and 89 minutes (100\u2003mg). There was no significant difference in migraine severity between the 2 groups. Parent Global Assessment was \u201cvery much\u201d or \u201cmuch improved\u201d in 6 of 7 (25\u2003mg) and 3 of 7 (100\u2003mg) patients. Migraine disability as measured by PedMidas\n                    <jats:sup>\u00a9<\/jats:sup>\n                    reduced from moderate to no disability (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u2003.001). There were no serious adverse events.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions.\u2014<\/jats:bold>\n                    Preventive therapy with topiramate resulted in reducing the overall migraine frequency and the frequency of attacks of BM at both 25\u2003mg and 100\u2003mg doses relative to the historical baseline and prospective baseline periods. The 2 treatment groups resulted in comparable outcomes.\n                  <\/jats:p>","DOI":"10.1111\/j.1526-4610.2007.00867.x","type":"journal-article","created":{"date-parts":[[2007,6,16]],"date-time":"2007-06-16T12:01:25Z","timestamp":1181995285000},"page":"1409-1417","source":"Crossref","is-referenced-by-count":35,"title":["A Double\u2010Blind, Dose Comparison Study of Topiramate for Prophylaxis of Basilar\u2010Type Migraine in Children: A Pilot Study"],"prefix":"10.1111","volume":"47","author":[{"given":"Donald","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Paradiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,12,3]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(61)92184-5"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1978.02120280062012"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.56.5.722"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1997.3701043.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.11.2034"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000147332.41993.90"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002761"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-2742"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.wco.0000169747.67653.f3"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.8.965"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.00262.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.6.811"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2005.00485.x"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1526-4610.2007.00867.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1526-4610.2007.00867.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T08:16:36Z","timestamp":1762071396000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/j.1526-4610.2007.00867.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.1111\/j.1526-4610.2007.00867.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1526-4610.2007.00867.x","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}